Approved by the House Energy and Commerce Health Subcommittee on 11 March, H.R. 5279 still lacks any concrete provisions regarding federal preemption of state and local requirements, though bill author and full committee chair Frank Pallone, D-NJ, remains committed to discussions on the subject. He recognized preemption as “a major issue that I know we have to deal with.”
Small business impacts, the safety of cosmetic products aimed at women of color, and per- and polyfluoroalkyl substances (PFAS) were key concerns voiced by House Energy and Commerce Health Subcommittee members during an 11 March markup of the Cosmetic Safety Enhancement Act.
In comparison, industry’s top priority, preemption, received modest attention.
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
